- Home
- OTLK vs LSTA Comparison
OTLK vs LSTA Comparison
Compare OTLK & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | LSTA |
|---|---|---|
| Founded | 2010 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 28.9M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | OTLK | LSTA |
|---|---|---|
| Price | $0.23 | $3.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 4.3M | 62.0K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $8,146,123.00 | ★ $35,283,868.00 |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.16 | $1.81 |
| 52 Week High | $3.39 | $5.07 |
Technical Indicators
Market Signals| Indicator | OTLK | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 37.28 |
| Support Level | $0.21 | $2.75 |
| Resistance Level | $0.29 | $3.43 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 24.53 | 36.61 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.